KANK deficiency leads to podocyte dysfunction and nephrotic syndromeHeon Yung Gee, Friedhelm Hildebrandt, Fujian Zhang et al.|Journal of Clinical Investigation|2015Cited by 200
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndromeOliver Groß, Markus Feldkoetter, Peter F. Hoyer et al.|Kidney International|2020Cited by 151
Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatmentShazia Ashraf, Assel Rakhmetova, Hiroki Kudo et al.|Nature Communications|2018Cited by 126
Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathyJohn F. O’Toole, Holger Prokisch, Yangjian Liu et al.|Journal of Clinical Investigation|2010Cited by 119